Open AccessSorafenib and sunitinib: A dermatologist′s perspective
Author(s) -
Vijendran Pragasam,
Rajesh Verma,
Biju Vasudevan
Publication year - 2014
Publication title -
indian dermatology online journal
Language(s) - English
Resource type - Journals
eISSN - 2249-5673
pISSN - 2229-5178
DOI - 10.4103/2229-5178.126017
Subject(s) - sorafenib , medicine , sunitinib , renal cell carcinoma , angiogenesis , hepatocellular carcinoma , adverse effect , grading (engineering) , oncology , dermatology , civil engineering , engineering
Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas. We discuss the pathophysiology, adverse cutaneous effects and their grading, potential high risk factors, role of gene polymorphism, critical period of hand-foot skin reaction development and their management.